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INTRODUCTION
Hydroxyurea (HU) is a cytoreductive agent commonly used
in the treatment of chronic myeloproliferative disorders. It
is usually well tolerated; however, long term HU therapy
has been associated with cutaneous side effects such as alope-
cia, diffuse hyperpigmentation, erythema, skin atrophy and
nail changes (1). Poikilodermatous dermatomyositis like skin
eruption with atrophy, erythema and scaling have also been
reported (2). Leg ulceration following HU therapy is less
common. Objective of this paper is to increase the awareness
of HU induced leg ulcers which will aid in the early diag-
nosis and appropriate treatment.
CASE REPORT
Case 1
54 yr old male patient with chronic myeliod leulemia
(CML) on HU 1.5 g/day since 1996 presented in June 2003
with bilateral perimalleolar ulcers. He had developed ulcers
6 months back, not preceded by trauma. Patient was a known
diabetic who was on oral hypoglycemic agents and was swi-
tched over to insulin since the onset of ulcers. He was treat-
ed with debridement and daily dressing for 6 months but the
ulcers did not heal. Examination revealed 1.5×2 cm perima-
lleolar ulcers on both the lateral malleoli covered by slough
with sloping edges, with no evidence of peripheral neuropa-
thy (Fig. 1). The lower limb pulsations were well felt and
there were no varicose veins. Investigations including total
leukocyte count, fasting and postprandial sugars, RFT, LFT
were normal. HU was discontinued and the ulcers healed in
3 months (Fig. 2). Patient was treated with busulphan as he
could not afford imatinib.
Case 2
46 yr old CML patient on HU therapy (1.5 g/day) since
2000 presented with bilateral leg ulcers in July 2003. Exami-
nation revealed bilateral lateral malleolar ulcers (Fig. 3), and
hepatosplenomegaly. There was no evidence of varicose veins
or peripheral neuropathy. Local wound treatment did not heal
the ulcers. Hydroxyurea was stopped and substituted with
imatinib mesylate. The ulcers healed completely in 2 months
and the disease was under control with the latter drug (Fig. 4).
Case 3
52 yr old male patient with polycythemia vera on HU 1
g/day, since September 1998 presented to us with painful
ulcer over the medial malleolus of left foot of 6 months dura-
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Hydroxyurea Induced Perimalleolar Ulcers
Hydroxyurea (HU) is an antineoplastic drug commonly used to treat chronic myelo-
proliferative disorders. Common dermatological side effects include hyperpigmen-
tation, scaling, erythema, alopecia, desquamation of face and hands. Leg ulcera-
tion following HU therapy is less common and very few cases have been reported
so far. Objective of this paper is to increase the awareness of hydroxyurea induced
leg ulcers which will aid in the early diagnosis and appropriate treatment. The first
case was a chronic myeloid leukemia (CML) patient on HU 1.5 g/day for 5 yr, who
had bilateral painful perimalleolar ulcers for 6 months. The second case was a CML
patient on HU 1.5 g/day for 3 yr who developed bilateral lateral malleolar ulcers.
Third case was a polycythemia vera (PV) patient on HU 1 g/day for 5 yr who pre-
sented with painful medial malleolar ulcer of 2 months. The last case of our report
was an elderly PV patient on HU 1.5 g/day for 2 yr and presented with lateral malle-
olar ulcer which persisted on reducing the dose of HU. In all the 4 cases the ulcers
healed on stopping HU. Our report confirms the association of chronic hydroxyurea
therapy and perimalleolar ulcers which respond promptly after discontinuation of
the drug. The heightened awareness among the physicians will promote early diag-
nosis and prompt relief from the agonizing ulcers.
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tion in 2003 with no history of preceding trauma. Past his-
tory was significant for a history of stripping of varicose veins
in 1992. Examination revealed a 1.5×3 cm ulcer over left
medial malleolus covered by slough with sloping edges, bilat-
eral varicose veins and hepatosplenomegaly. Peripheral pul-
sations were well felt. A differential diagnosis of HU ulcer
and venous ulcer were considered. The Doppler study showed
normal study of deep venous system of lower limbs with no
evidence of saphenofemoral or saphenopopliteal incompe-
tence. There were superficial varicosities along the medial
aspect of legs and thighs. The biopsy of the ulcer showed
granulation tissue composed of proliferating capillaries lined
by plump endothelial cells surrounded by sparse chronic
inflammatory infiltrate overlying fibrocollagenous tissue.
Surface was covered by cell debris, fibrin and acute inflam-
matory cells. HU was considered in view of painful non heal-
ing nature of the ulcer. The drug was stopped and the ulcer
healed promptly in 3 weeks.
Case 4
66 yr old patient with polycythemia vera on HU 1.5 g/day
Fig. 1. Ulcer over the lateral malleolus (Case 1).
Fig. 3. Ulcer over the lateral malleolus (Case 2).
Fig. 2. Healed scar over the lateral malleolus (Case 1).
Fig. 4. Healed scar over the lateral malleolus (Case 2).Hydroxyurea-induced Perimalleolar Ulcer 179
since February 2000 presented in July 2002 with an ulcer
on the right lateral malleolus. Local antibiotics, compression
stockings and daily wound dressing failed to heal the ulcer.
On examination there was an ulcer on the right lateral malle-
olus with a size of 1.5×3 cm, and hepatosplenomegaly. There
were no varicose veins in the lower limbs. HU dose was dec-
reased to 500 mg/day, but the ulcer persisted. Finally HU
was stopped and the patient was advised regular phleboto-
my. The ulcer healed promptly in 6 weeks.
DISCUSSION
Stahl and Silber first reported HU related skin ulcers in
1985 (3). Frequently such ulcers occur over the malleoli. One
explanation for such perimalleolar predilection is the fre-
quently occurring trauma to this site. Histology examina-
tion of the edge of the ulcer showed non diagnostic changes.
In our case series of 4 patients, non-traumatic perimalleolar
ulcers developed while they were on long term treatment
with HU for polycythemia vera or CML. The duration of
HU therapy ranged from 2.5 yr to 7 yr and the cumulative
dose was 1.3 kg to 3.7 kg prior to the ulcer development.
Efforts to initiate wound healing before discontinuation of
treatment included the use of topical and systemic antibiotic
therapy, topical prednisone and topical wound dressings, but
with no significant clinical benefit. Our case series indicates
that even with meticulous wound care, resolution of the ulcers
usually requires discontinuation of HU treatment. 
Insidious onset, indolent behaviour and prompt healing
after stopping HU suggest that the mechanism for cutaneous
toxicity is progressive but reversible cytological damage. HU
converts a free radical nitroxide in vivo and inhibits DNA
repair (4). Cellular injury accumulates to the extent that repair
mechanisms can no longer regenerate viable, normal func-
tioning epidermis, stromal cells or endothelium and tissue
damage and ulcers therefore develop (4).
In a review of 14 patients published from the Mayo Clinic,
typical site was perimalleolar region with rare sites being the
front of the leg, feet and the calf. Multiple ulcers were seen
in 9 patients. The ulcers were extremely painful. The average
cumulative dose of HU, which the patient received prior to
ulcer development, ranged from 1.4 kg to 5.5 kg. The dura-
tion of HU treatment ranged from 2 to 15 yr. HU was dis-
continued in all patients and ulcer healed spontaneously in
12 patients within 2 to 6 months and grafting was done in
2 patients. Two patients developed ulcer after treatment was
restarted (5). Montefusco and colleagues described 17 patients
who had HU related leg ulcers and found complete resolu-
tion (14 patients) or marked improvement (3 patients) after
HU therapy was discontinued (6).
Our case series summarized here highlights the association
between HU treatment and the development of perimalleo-
lar ulcers in the leg. Our report also confirms the failure of
local or systemic antibiotics and the local dressings in curing
HU ulcers, and the necessity for discontinuation of the drug
and search for alternative therapy once this unusual toxicity
develops. We hope that increased awareness of this associa-
tion will promote early diagnosis and proper management
of these ulcers. 
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